Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 195

1.

Catechins prevent vascular smooth muscle cell invasion by inhibiting MT1-MMP activity and MMP-2 expression.

El Bedoui J, Oak MH, Anglard P, Schini-Kerth VB.

Cardiovasc Res. 2005 Aug 1;67(2):317-25.

PMID:
15885676
3.

Green tea polyphenol epigallocatechin-3-gallate suppresses rat hepatic stellate cell invasion by inhibition of MMP-2 expression and its activation.

Zhen MC, Huang XH, Wang Q, Sun K, Liu YJ, Li W, Zhang LJ, Cao LQ, Chen XL.

Acta Pharmacol Sin. 2006 Dec;27(12):1600-7.

4.

Mechanisms of the inhibitory effect of epigallocatechin-3-gallate on cultured human vascular smooth muscle cell invasion.

Cheng XW, Kuzuya M, Nakamura K, Liu Z, Di Q, Hasegawa J, Iwata M, Murohara T, Yokota M, Iguchi A.

Arterioscler Thromb Vasc Biol. 2005 Sep;25(9):1864-70. Epub 2005 Jul 28.

5.

(-)Epigallocatechin-3-gallate directly inhibits MT1-MMP activity, leading to accumulation of nonactivated MMP-2 at the cell surface.

Dell'Aica I, Donà M, Sartor L, Pezzato E, Garbisa S.

Lab Invest. 2002 Dec;82(12):1685-93.

PMID:
12480918
6.

Tumor gelatinases and invasion inhibited by the green tea flavanol epigallocatechin-3-gallate.

Garbisa S, Sartor L, Biggin S, Salvato B, Benelli R, Albini A.

Cancer. 2001 Feb 15;91(4):822-32.

PMID:
11241252
7.

Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques: evidence for activation by proinflammatory mediators.

Rajavashisth TB, Xu XP, Jovinge S, Meisel S, Xu XO, Chai NN, Fishbein MC, Kaul S, Cercek B, Sharifi B, Shah PK.

Circulation. 1999 Jun 22;99(24):3103-9.

8.

Green tea catechins inhibit the cultured smooth muscle cell invasion through the basement barrier.

Maeda K, Kuzuya M, Cheng XW, Asai T, Kanda S, Tamaya-Mori N, Sasaki T, Shibata T, Iguchi A.

Atherosclerosis. 2003 Jan;166(1):23-30.

PMID:
12482547
10.
12.

Inhibitory effects of green tea polyphenol (-)-epigallocatechin gallate on the expression of matrix metalloproteinase-9 and on the formation of osteoclasts.

Yun JH, Pang EK, Kim CS, Yoo YJ, Cho KS, Chai JK, Kim CK, Choi SH.

J Periodontal Res. 2004 Oct;39(5):300-7.

PMID:
15324350
13.

Effects of tea polyphenols on the invasion and matrix metalloproteinases activities of human fibrosarcoma HT1080 cells.

Maeda-Yamamoto M, Kawahara H, Tahara N, Tsuji K, Hara Y, Isemura M.

J Agric Food Chem. 1999 Jun;47(6):2350-4.

PMID:
10794635
14.
15.

Probing the infiltrating character of brain tumors: inhibition of RhoA/ROK-mediated CD44 cell surface shedding from glioma cells by the green tea catechin EGCg.

Annabi B, Bouzeghrane M, Moumdjian R, Moghrabi A, Béliveau R.

J Neurochem. 2005 Aug;94(4):906-16. Epub 2005 Jun 30.

16.

(-)-Epigallocatechin gallate inhibits membrane-type 1 matrix metalloproteinase, MT1-MMP, and tumor angiogenesis.

Yamakawa S, Asai T, Uchida T, Matsukawa M, Akizawa T, Oku N.

Cancer Lett. 2004 Jul 8;210(1):47-55.

PMID:
15172120
17.

Inhibition of matrix metalloproteinase-14 in osteosarcoma cells by clodronate.

Heikkilä P, Teronen O, Hirn MY, Sorsa T, Tervahartiala T, Salo T, Konttinen YT, Halttunen T, Moilanen M, Hanemaaijer R, Laitinen M.

J Surg Res. 2003 May 1;111(1):45-52.

PMID:
12842447
18.

Membrane type 1-matrix metalloproteinase is activated during migration of human endothelial cells and modulates endothelial motility and matrix remodeling.

Gálvez BG, Matías-Román S, Albar JP, Sánchez-Madrid F, Arroyo AG.

J Biol Chem. 2001 Oct 5;276(40):37491-500. Epub 2001 Jul 11.

19.

Multifunctional effect of epigallocatechin-3-gallate (EGCG) in downregulation of gelatinase-A (MMP-2) in human breast cancer cell line MCF-7.

Sen T, Moulik S, Dutta A, Choudhury PR, Banerji A, Das S, Roy M, Chatterjee A.

Life Sci. 2009 Feb 13;84(7-8):194-204. doi: 10.1016/j.lfs.2008.11.018. Epub 2008 Dec 3.

PMID:
19105967
20.

Anti-atherogenic effects of a mixture of ascorbic acid, lysine, proline, arginine, cysteine, and green tea phenolics in human aortic smooth muscle cells.

Ivanov V, Roomi MW, Kalinovsky T, Niedzwiecki A, Rath M.

J Cardiovasc Pharmacol. 2007 Mar;49(3):140-5.

PMID:
17414225

Supplemental Content

Support Center